Clinical TrialsImmunovant kicked off its first potentially registrational trial with IMVT-1402 in Graves’ disease patients who are hyperthyroid despite treatment with ATDs, indicating a proactive approach to addressing unmet needs.
Management And Strategic DirectionIMVT recently announced several corporate changes which more closely aligned IMVT's new management team under ROIV's strategic direction for the company.
Therapies DevelopmentThere is growing interest in more targeted, disease-modifying therapies such as IMVT-1402, which aims to address the disease by reducing pathogenic IgG autoantibodies.